Pterygium of the Conjunctiva and Cornea
Conditions
Keywords
Bevacizumab, impending recurrent pterygium
Brief summary
Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, preventing or retarding the progression of recurrence.
Detailed description
1. Impending recurrent pterygium 2. Anti-VEGF therapy * Bevacizumab * Subconjunctival injection * Suppress neovascularization
Interventions
DRUGFluorometholone
topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
DRUGBevacizumab
subconjunctival bevacizumab 1.25 mg/0.05mL
Sponsors
Ramathibodi Hospital
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
1. Impending recurrent pterygium developed within 6 months following pterygium surgery either simple excision or excision with grafting. 2. Failure of conventional topical anti-inflammatory therapy for impending recurrent pterygium which was defined by the progression of fibrovascular tissue over the excised area despite receiving treatment. 3. No history of any adjunctive treatment such as MMC, 5-FU, periocular injection of corticosteroids and beta radiation. 4. No other ocular surface pathologies or coexisting ocular diseases. 5. No other ocular surgeries within the previous 6 months. 6. No history of allergy to the medications used in this study. 7. Good compliance with the study regimen and availability for the duration of the entire study period.
Exclusion criteria
1. Platelet disorders 2. Hypertension 3. Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of impending recurrent pterygium | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Visual analog scales | 3 months |
| Adverse reactions | 3 months |
Countries
Thailand
Outcome results
None listed